Ideas Overview

Introduction

This page provides an overview of therapeutic concepts and ideas for neurodegenerative diseases generated through NeuroWiki's knowledge synthesis. These ideas represent novel combinations of existing mechanistic evidence with therapeutic hypotheses. [@cummings2024]

Therapeutic Concept Categories

Disease-Modifying Approaches

| Category | Target | Rationale | Status | [@kalia2023]
|----------|--------|-----------|--------|
| Amyloid Reduction | [Aβ](/proteins/amyloid-beta) production/clearance | Core pathology | In clinical trials |
| [Tau](/proteins/tau) Modulation | Phosphorylation/aggregation | Spreading mechanism | In clinical trials |
| [Alpha-synuclein](/proteins/alpha-synuclein) | Aggregation inhibitors | PD core pathology | Phase 2 |
| Neuroprotection | Multiple pathways | Broad benefit | Preclinical |

Symptomatic Approaches

| Category | Target | Rationale | Status |
|----------|--------|-----------|--------|
| Cognitive Enhancement | Glutamatergic signaling | Memory improvement | Approved |
| Motor Modulation | Dopaminergic system | Motor function | Approved |
| Behavioral Control | Serotonergic system | Neuropsychiatric | Approved |

Idea Generation Methodology

Evidence Synthesis

Literature mining: Extract mechanisms from publications

Pathway analysis: Map gene-protein-disease relationships

Target identification: Find druggable nodes

Hypothesis formation: Propose novel interventions

Feasibility assessment: Evaluate translatability

Prioritization Criteria

...

Introduction

This page provides an overview of therapeutic concepts and ideas for neurodegenerative diseases generated through NeuroWiki's knowledge synthesis. These ideas represent novel combinations of existing mechanistic evidence with therapeutic hypotheses. [@cummings2024]

Therapeutic Concept Categories

Disease-Modifying Approaches

| Category | Target | Rationale | Status | [@kalia2023]
|----------|--------|-----------|--------|
| Amyloid Reduction | [Aβ](/proteins/amyloid-beta) production/clearance | Core pathology | In clinical trials |
| [Tau](/proteins/tau) Modulation | Phosphorylation/aggregation | Spreading mechanism | In clinical trials |
| [Alpha-synuclein](/proteins/alpha-synuclein) | Aggregation inhibitors | PD core pathology | Phase 2 |
| Neuroprotection | Multiple pathways | Broad benefit | Preclinical |

Symptomatic Approaches

| Category | Target | Rationale | Status |
|----------|--------|-----------|--------|
| Cognitive Enhancement | Glutamatergic signaling | Memory improvement | Approved |
| Motor Modulation | Dopaminergic system | Motor function | Approved |
| Behavioral Control | Serotonergic system | Neuropsychiatric | Approved |

Idea Generation Methodology

Evidence Synthesis

Literature mining: Extract mechanisms from publications

Pathway analysis: Map gene-protein-disease relationships

Target identification: Find druggable nodes

Hypothesis formation: Propose novel interventions

Feasibility assessment: Evaluate translatability

Prioritization Criteria

• Mechanistic plausibility: Strong biological rationale
• Druggability: Existing or developable interventions
• Safety margin: Acceptable side effect profile
• Patient need: Unmet medical need
• Commercial potential: Market opportunity

Active Research Themes

Multi-Target Approaches

Combining multiple mechanisms:

• Amyloid + tau + neuroinflammation
• Gene therapy + small molecule
• Cell therapy + neurotrophic factors

Precision Medicine

Genetic and biomarker-driven approaches:

• [APOE](/proteins/apoe)-targeted therapies
• Mutation-specific interventions
• Biomarker-selected patient populations

Regenerative Medicine

Restoring lost function:

• Stem cell transplantation
• Gene replacement therapy
• Tissue engineering

Idea Implementation Pipeline

Stage 1: Concept

• Literature-based hypothesis
• Mechanistic rationale
• Target identification

Stage 2: Validation

• In vitro studies
• Animal models
• Biomarker development

Stage 3: Translation

• Clinical trial design
• Regulatory strategy
• Commercial assessment

Stage 4: Development

• IND-enabling studies
• Phase 1-3 trials
• Commercialization

Notable Idea Categories

Combination Therapies

• Amyloid immunotherapy + tau modulator
• Neuroinflammation inhibitor + neurotrophic factor
• Gene therapy + rehabilitation

Repurposing Opportunities

| Drug | Original Use | Neurodegeneration Potential |
|------|--------------|----------------------------|
| Metformin | Diabetes | Neuroprotection |
| Saracatinib | Cancer | Src inhibition |
| Losartan | Hypertension | AT1R blockade |
| Ibuprofen | Pain | Anti-inflammatory |

Novel Delivery

• Intranasal neurotrophic factors
• Focused ultrasound [blood-brain barrier](/entities/blood-brain-barrier) opening
• Exosome-mediated delivery

Success Metrics

For Concepts

• Mechanistic evidence strength
• Therapeutic index
• Development feasibility

For Programs

• Preclinical efficacy
• Clinical translatability
• Commercial viability

Related Pages

• [Ideas Index](/ideas)
• [Idea Rankings](/ideas/rankings)
• [Mechanisms](/mechanisms)
• [Treatments](/therapeutics)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Cross-Links

Disease Overview Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [FTD](/diseases/frontotemporal-dementia)

Key Mechanisms

• [Amyloid Cascade](/mechanisms/amyloid-cascade)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

Treatment Approaches

• [Immunotherapy](/therapeutics/immunotherapy)
• [Gene Therapy](/therapeutics/gene-therapy)
• [Small Molecule Therapy](/therapeutics/small-molecule-therapy)
• [Cell Therapy](/therapeutics/cell-therapy-neurodegeneration)

Related Index Pages

• [Genes Overview](/genes/overview) — Genetic targets and risk factors
• [Proteins Overview](/proteins/overview) — Protein targets and modulators
• [Diagnostics Overview](/diagnostics/overview) — Diagnostic methods and biomarkers
• [Brain Regions Overview](/brain-regions/overview) — Brain regions affected
• [Diseases Overview](/diseases/overview) — Disease classifications

Topics

• [Ideas Overview](/ideas/overview) — This page
• [Ideas Rankings](/ideas/rankings) — Ranked list by research activity
• [Ideas Dashboard](/ideas/dashboard) — Data visualizations and metrics

Summary Statistics

• Total Pages: 98 Ideas pages in this section
• Last Updated: This section is actively maintained

A-Z All Pages

• [ACSL4 Inhibition for Ferroptosis Prevention in Neurodegeneration](/ideas/acsl4-inhibition-ferroptosis-prevention)
• [Adenine Base Editing of APOE4 to APOE3 for Alzheimer's Prevention](/ideas/payload-base-editing-apoe4)
• [Astrocyte Glutamate-Buffer Rescue with EAAT2 Transcription Reboot](/ideas/payload-eeat2-glutamate-buffer-rescue)
• [Astrocyte Glutamate-Buffer Rescue: EAAT2 Transcription Reboot Therapy](/ideas/payload-eaat2-glutamate-buffer-rescue)
• [Astrocyte-to-Neuron Reprogramming Therapy](/ideas/astrocyte-neuron-reprogramming)
• [Astrocytic Mitochondrial Transfer + Metabolic Copacking](/ideas/astrocytic-mitochondrial-transfer-metabolic-copacking)
• [Autophagy-Proteostasis Dual Activation](/ideas/autophagy-proteostasis-dual-activation)
• [BBB Transcytosis Shuttle for Episodic CNS PROTAC Delivery](/ideas/bbb-transcytosis-protac)
• [BBB-Transcytosis Shuttle for Episodic CNS PROTAC Delivery](/ideas/bbb-transcytosis-shuttle-protac-delivery)
• [C9orf72 RNA-Targeting Dipeptide Repeat Reduction](/ideas/c9orf72-rna-targeting-dpr-reduction)
• [CB1 Receptor Endocannabinoid Modulation for Neuroprotection](/ideas/cb1-endocannabinoid-modulation-therapy)
• [CD38 Inhibition + NAD+ Precursor Synergy for Neuroprotection](/ideas/cd38-inhibition-nad-synergy)
• [CNS-Selective NLRP3 Inflammasome Inhibitor](/ideas/cns-nlrp3-inflammasome-inhibitor)
• [CRISPRi Epigenetic Silencing of SNCA for Parkinson's Disease](/ideas/payload-crispri-snca-silencing)
• [CSF1R Modulation Therapy: Microglia Reset Protocol](/ideas/csf1r-modulation-microglia-reset)
• [CSF1R-Targeted Microglia Therapy](/ideas/csf1r-microglia-therapy)
• [CSPG-PNN Modulation for Synaptic Plasticity Enhancement](/ideas/payload-cspg-pnn-modulation-synaptic-plasticity)
• [Calcineurin-NFAT Pathway Modulation for Neurodegeneration](/ideas/calcineurin-nfat-pathway-modulation)
• [Cathepsin D Activation Therapy for Lysosomal Proteostasis](/ideas/payload-ctsd-lysosomal-proteostasis)
• [Circadian-Neuroimmune Coupling: Clock Restoration + Sleep Enhancement](/ideas/combo-circadian-sleep-neuroimmune)
• [Combination Logic Ideas — Cross-Modality Pairings](/ideas/combination-logic-ideas)
• [Digital Therapeutics for Neurodegeneration Investment Analysis](/ideas/digital-therapeutics-neurodegeneration-investment)
• [Dual Proteinopathy Immunotherapy: Aβ + pTau/pα-Syn Bispecific](/ideas/combo-amyloid-tau-alpha-syn-bspecific)
• [Engineered Exosomes for Intranasal CNS Delivery](/ideas/delivery-exosome-nasal)
• [Engineered iPSC-Microglia Cell Therapy for Neurodegeneration](/ideas/payload-ipsc-microglia-therapy)
• [Epigenetic-Metabolic Coupling: SIRT1 Activator + NAD+ Precursor](/ideas/combo-sirt1-nad-epigenetic-metabolic)
• [FSP1-CoQ10 Redox Augmentation Therapy for Neurodegeneration](/ideas/fsp1-coq10-redox-augmentation)
• [FUS Protein-Targeting Therapy for ALS/FTD](/ideas/payload-fus-protein-targeting-therapy)
• [Ferroptosis Inhibition Therapy](/ideas/payload-ferroptosis-inhibitor)
• [Focused Ultrasound-Enhanced Nanoparticle Delivery](/ideas/delivery-focused-ultrasound-nanoparticle)

[See all 98 ideas pages...](/ideas/rankings)

References

[Cummings J, et al., Alzheimer's disease drug development. Alzheimer's Dement. 2024 (2024)](https://doi.org/10.1002/alz.13802)

[Kalia LV, et al., Parkinson's disease: pathogenesis. Lancet Neurol. 2023 (2023)](https://doi.org/10.1016/S1474-4422(23)